Losartan reverses permissive epigenetic changes in renal glomeruli of diabetic db/db mice

Kidney International

Volumn 85, Issue 2, 2014, Pages 362-373

  Reddy, Marpadga A ^a   Sumanth, Putta ^a   Lanting, Linda ^a   Yuan, Hang ^a   Wang, Mei ^a   Mar, Daniel ^b   Alpers, Charles E ^c   Bomsztyk, Karol ^b   Natarajan, Rama ^a  

^a CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF WASHINGTON   (United States)

Author keywords

angiotensin II; diabetic nephropathy; epigenetics; gene regulation; losartan

Indexed keywords

GLUCOSE; LOSARTAN; RNA POLYMERASE II;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; DIABETIC NEPHROPATHY; DRUG EFFICACY; DRUG RESPONSE; EPIGENETICS; GENE; GENE EXPRESSION; GLUCOSE BLOOD LEVEL; HISTONE MODIFICATION; HYPERTENSION; MALE; MCP 1 GENE; MESANGIUM CELL; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PAI I GENE; PRIORITY JOURNAL; RAGE GENE; SYSTOLIC BLOOD PRESSURE; TRANSCRIPTION REGULATION;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANIMALS; BLOOD PRESSURE; CELLS, CULTURED; CHEMOKINE CCL2; CHROMATIN ASSEMBLY AND DISASSEMBLY; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; DISEASE MODELS, ANIMAL; DNA METHYLATION; EPIGENESIS, GENETIC; EXTRACELLULAR MATRIX PROTEINS; GENE EXPRESSION REGULATION; HISTONES; INFLAMMATION MEDIATORS; KIDNEY GLOMERULUS; LOSARTAN; MALE; MICE; NUCLEOSOMES; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROMOTER REGIONS, GENETIC; RECEPTORS, IMMUNOLOGIC; RNA POLYMERASE II; TRANSFECTION;

EID: 84895902886     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/ki.2013.387     Document Type: Article

References (46)

1. Kanwar YS, Sun L, Xie P et al. A glimpse of various pathogenetic mechanisms of diabetic nephropathy. Annu Rev Pathol 2011; 6: 395-423
2. Ruggenenti P, Cravedi P, Remuzzi G. The RAAS in the pathogenesis and treatment of diabetic nephropathy. Nat Rev Nephrol 2010; 6: 319-330
3. Tesch GH, Lim AK. Recent insights into diabetic renal injury from the db/db mouse model of type 2 diabetic nephropathy. Am J Physiol Renal Physiol 2011; 300: F301-F310
4. Calcutt NA, Cooper ME, Kern TS et al. Therapies for hyperglycaemiainduced diabetic complications: From animal models to clinical trials. Nat Rev Drug Discov 2009; 8: 417-429
5. Sanchez AP, Sharma K. Transcription factors in the pathogenesis of diabetic nephropathy. Expert Rev Mol Med 2009; 11: E13
6. Kouzarides T. Chromatin modifications and their function. Cell 2007; 128: 693-705
7. Portela A, Esteller M. Epigenetic modifications and human disease. Nat Biotechnol 2010; 28: 1057-1068
8. Ling C, Groop L. Epigenetics: A molecular link between environmental factors and type 2 diabetes. Diabetes 2009; 58: 2718-2725
9. Villeneuve LM, Natarajan R. The role of epigenetics in the pathology of diabetic complications. Am J Physiol Renal Physiol 2010; 299: F14-F25
10. Pirola L, Balcerczyk A, Okabe J et al. Epigenetic phenomena linked to diabetic complications. Nat Rev Endocrinol 2010; 6: 665-675
11. Reddy MA, Natarajan R. Epigenetics in diabetic kidney disease. J Am Soc Nephrol 2011; 22: 2182-2185
12. El-Osta A, Brasacchio D, Yao D et al. Transient high glucose causes persistent epigenetic changes and altered gene expression during subsequent normoglycemia. J Exp Med 2008; 205: 2409-2417
13. Villeneuve LM, Reddy MA, Lanting LL et al. Epigenetic histone H3 lysine 9 methylation in metabolic memory and inflammatory phenotype of vascular smooth muscle cells in diabetes. Proc Natl Acad Sci USA 2008; 105: 9047-9052
14. Zhong Q, Kowluru RA. Epigenetic changes in mitochondrial superoxide dismutase in the retina and the development of diabetic retinopathy. Diabetes 2011; 60: 1304-1313
15. Miao F, Chen Z, Zhang L et al. Profiles of epigenetic histone posttranslational modifications at type 1 diabetes susceptible genes. J Biol Chem 2012; 287: 16335-16345
16. Pirola L, Balcerczyk A, Tothill RW et al. Genome-wide analysis distinguishes hyperglycemia regulated epigenetic signatures of primary vascular cells. Genome Res 2011; 21: 1601-1615
17. Nelson JD, Flanagin S, Kawata Y et al. Transcription of laminin gamma1 chain gene in rat mesangial cells: Constitutive and inducible RNA polymerase II recruitment and chromatin states. Am J Physiol Renal Physiol 2008; 294: F525-F533
18. Naito M, Bomsztyk K, Zager RA. Renal ischemia-induced cholesterol loading: Transcription factor recruitment and chromatin remodeling along the HMG CoA reductase gene. Am J Pathol 2009; 174: 54-62
19. Naito M, Zager RA, Bomsztyk K. BRG1 increases transcription of proinflammatory genes in renal ischemia. J Am Soc Nephrol 2009; 20: 1787-1796
20. Sun G, Reddy MA, Yuan H et al. Epigenetic histone methylation modulates fibrotic gene expression. J Am Soc Nephrol 2010; 21: 2069-2080
21. Decleves AE, Sharma K. New pharmacological treatments for improving renal outcomes in diabetes. Nat Rev Nephrol 2010; 6: 371-380
22. Kagami S, Border WA, Miller DE et al. Angiotensin II stimulates extracellular matrix protein synthesis through induction of transforming growth factor-beta expression in rat glomerular mesangial cells. J Clin Invest 1994; 93: 2431-2437
23. Thomas MC, Tikellis C, Burns WM et al. Interactions between renin angiotensin system and advanced glycation in the kidney. J Am Soc Nephrol 2005; 16: 2976-2984
24. Brenner BM, Cooper ME, de Zeeuw D et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001; 345: 861-869
25. Flanagin S, Nelson JD, Castner DG et al. Microplate-based chromatin immunoprecipitation method, Matrix ChIP: A platform to study signaling of complex genomic events. Nucleic Acids Res 2008; 36: E17
26. Barski A, Cuddapah S, Cui K et al. High-resolution profiling of histone methylations in the human genome. Cell 2007; 129: 823-837
27. Yuan H, Reddy MA, Sun G et al. Involvement of p300/CBP and epigenetic histone acetylation in TGF-beta1-mediated gene transcription in mesangial cells. Am J Physiol Renal Physiol 2013; 304: F601-F613
28. Nelson JD, LeBoeuf RC, Bomsztyk K. Direct recruitment of insulin receptor and ERK signaling cascade to insulin-inducible gene loci. Diabetes 2011; 60: 127-137
29. Miao F, Gonzalo IG, Lanting L et al. In vivo chromatin remodeling events leading to inflammatory gene transcription under diabetic conditions. J Biol Chem 2004; 279: 18091-18097
30. Das F, Ghosh-Choudhury N, Venkatesan B et al. Akt kinase targets association of CBP with SMAD 3 to regulate TGFbeta-induced expression of plasminogen activator inhibitor-1. J Cell Physiol 2008; 214: 513-527
31. Li Y, Reddy MA, Miao F et al. Role of the histone H3 lysine 4 methyltransferase, SET7/9, in the regulation of NF-kappaB-dependent inflammatory genes. Relevance to diabetes and inflammation. J Biol Chem 2008; 283: 26771-26781
32. Komers R, Mar D, Denisenko O et al. Epigenetic changes in renal genes dysregulated in mouse and rat models of type 1 diabetes. Lab Invest 2013; 93: 543-552
33. Allis CD, Berger SL, Cote J et al. New nomenclature for chromatinmodifying enzymes. Cell 2007; 131: 633-636
34. Moore MJ. From birth to death: The complex lives of eukaryotic mRNAs. Science 2005; 309: 1514-1518
35. Shanmugam N, Ransohoff RM, Natarajan R. Interferon-gamma-inducible protein (IP)-10 mRNA stabilized by RNA-binding proteins in monocytes treated with S100b. J Biol Chem 2006; 281: 31212-31221
36. Shanmugam N, Reddy MA, Natarajan R. Distinct roles of heterogeneous nuclear ribonuclear protein K and microRNA-16 in cyclooxygenase-2 RNA stability induced by S100b, a ligand of the receptor for advanced glycation end products. J Biol Chem 2008; 283: 36221-36233
37. Kato M, Wang L, Putta S et al. Posttranscriptional upregulation of Tsc-22 by Ybx1, a target of miR-216a, mediates TGF-{beta}-induced collagen expression in kidney cells. J Biol Chem 2010; 285: 34004-34015
38. Dhawan L, Liu B, Pytlak A et al. Y-box binding protein 1 and RNase UK114 mediate monocyte chemoattractant protein 1 mRNA stability in vascular smooth muscle cells. Mol Cell Biol 2012; 32: 3768-3775
39. Reddy MA, Jin W, Villeneuve L et al. Pro-inflammatory role of microrna-200 in vascular smooth muscle cells from diabetic mice. Arterioscler Thromb Vasc Biol 2012; 32: 721-729
40. Kato M, Arce L, Wang M et al. A microRNA circuit mediates transforming growth factor-beta1 autoregulation in renal glomerular mesangial cells. Kidney Int 2011; 80: 358-368
41. Wong WT, Tian XY, Xu A et al. Angiotensin II type 1 receptor-dependent oxidative stress mediates endothelial dysfunction in type 2 diabetic mice. Antioxid Redox Signal 2010; 13: 757-768
42. Singh R, Alavi N, Singh AK et al. Role of angiotensin II in glucose-induced inhibition of mesangial matrix degradation. Diabetes 1999; 48: 2066-2073
43. Mauer M, Zinman B, Gardiner R et al. Renal and retinal effects of enalapril and losartan in type 1 diabetes. N Engl J Med 2009; 361: 40-51
44. Yuan H, Lanting L, Xu ZG et al. Effects of cholesterol-Tagged small interfering RNAs targeting 12/15-lipoxygenase on parameters of diabetic nephropathy in a mouse model of type 1 diabetes. Am J Physiol Renal Physiol 2008; 295: F605-F617
45. Putta S, Lanting L, Sun G et al. Inhibiting microRNA-192 ameliorates renal fibrosis in diabetic nephropathy. J Am Soc Nephrol 2012; 23: 458-469
46. Yu J, Feng Q, Ruan Y et al. Microplate-based platform for combined chromatin and DNA methylation immunoprecipitation assays. BMC Mol Biol 2011; 12: 49